Novel compounds

Abstract

This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals.

1 . A method of treating a disease or disorder where an antagonist of a human orexin receptor is required, which comprises administering to a subject in need thereof an effective amount of a compound of formula (I): 
       
         
           
           
               
               
           
         
         where Ar is selected from the group consisting of formula: 
       
       
         
           
           
               
               
           
         
         
           R 1  is (C 1-4 )alkyl, halo, halo(C 1-4 )alkyl, (C 1-4 )alkoxy, halo(C 1-4 )alkoxy, (C 1-4 )alkyl-O—(C 1-4 )alkyl, CN, NR 5 R 6  wherein R 5  is H or (C 1-4 )alkyl and R 6  is H or (C 1-4 )alkyl; 
           R 2  is (C 1-4 )alkyl, halo, halo(C 1-4 )alkyl, (C 1-4 )alkoxy, halo(C 1-4 )alkoxy, (C 1-4 )alkyl-O—(C 1-4 )alkyl, CN, NR 7 R 8  wherein R 7  is H or (C 1-4 -alkyl and R 8  is H or (C 1-4 )-alkyl; 
           R 3  is (C 1-4 )alkyl, halo, halo(C 1-4 )alkyl, (C 1-4 )alkoxy, halo(C 1-4 )alkoxy, (C 1-4 )alkyl-O—(C 1-4 )alkyl, CN, NR 9 R 10  wherein R 9  is H or (C 1-4 -alkyl and R 10  is H or (C 1-4 )-alkyl; 
           n is 0 or 1; p is 0 or 1; and q is 0 or 1; 
           with the proviso that p and q are not both 0; 
           or a pharmaceutically acceptable salt thereof, 
           wherein the disease or disorder is a sleep disorder, a depression or mood disorder, an anxiety disorder, a substance-related disorder or a feeding disorder. 
         
       
     
     
         2 . The method according to  claim 1 , where the disease or disorder is a sleep disorder. 
     
     
         3 . The method according to  claim 2 , where the sleep disorder is selected from the group consisting of Primary Insomnia (307.42), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45), Dyssomnia Not Otherwise Specified (307.47); Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46), Parasomnia Not Otherwise Specified (307.47); Insomnia Related to Another Mental Disorder (307.42), Sleep Disorder Due to a General Medical Condition, selected from sleep disturbances associated with neurological disorders, neuropathic pain, restless leg syndrome, heart or lung diseases; and a Substance-Induced Sleep Disorder selected from Insomnia Type, Parasomnia Type and Mixed Type; Sleep Apnea and Jet-Lag Syndrome. 
     
     
         4 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II) and n is 0. 
     
     
         5 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 1, q is 0 and R 2  is (C 1-4 )alkyl. 
     
     
         6 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 1, q is 0 and R 2  is methyl. 
     
     
         7 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 0, q is 1 and R 3  is (C 1-4 )alkyl. 
     
     
         8 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 0, q is 1 and R 3  is methyl. 
     
     
         9 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 1, q is 1, R 2  is (C 1-4 )alkyl and R 3  is (C 1-4 )alkyl. 
     
     
         10 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (II), n is 0, p is 1, q is 1, R 2  is methyl and R 3  is methyl. 
     
     
         11 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III) and n is 0. 
     
     
         12 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 1, q is 0 and R 2  is (C 1-4 )alkyl. 
     
     
         13 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 1, q is 0 and R 2  is methyl. 
     
     
         14 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 0, q is 1 and R 3  is (C 1-4 )alkyl. 
     
     
         15 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 0, q is 1 and R 3  is methyl. 
     
     
         16 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 1, q is 1, R 2  is (C 1-4 )alkyl and R 3  is (C 1-4 )alkyl. 
     
     
         17 . The method according to  claim 1 , where, in the compound of Formula (I), or pharmaceutically acceptable salt thereof, Ar is a group of formula (III), n is 0, p is 1, q is 1, R 2  is methyl and R 3  is methyl. 
     
     
         18 . The method according to  claim 1 , where the compound of Formula (I) is 6,8-dimethyl-2-({(2S)-1-[(2-methyl-5-phenyl-1,3-thiazol-4-yl)carbonyl]-2-piperidinyl}methyl)imidazo[1,2-a]pyrazine, or pharmaceutically acceptable salt thereof.